Relay Therapeutics, Inc.
RLAY
$2.90
-$0.21-6.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.26% | -60.83% | -61.22% | 3,637.58% | 2,873.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.26% | -60.83% | -61.22% | 3,637.58% | 2,873.65% |
| Cost of Revenue | -5.86% | -3.35% | 2.66% | 9.24% | 18.89% |
| Gross Profit | -2.94% | -1.53% | -8.33% | 2.12% | -6.47% |
| SG&A Expenses | 0.48% | 2.11% | 2.80% | 4.41% | 8.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.63% | -2.29% | 2.69% | 8.27% | 16.65% |
| Operating Income | -2.41% | -1.65% | -7.16% | 0.81% | -6.83% |
| Income Before Tax | -1.30% | 1.25% | -5.90% | 6.27% | -1.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.30% | 1.25% | -5.90% | 6.27% | -1.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.30% | 1.25% | -5.90% | 6.27% | -1.99% |
| EBIT | -2.41% | -1.65% | -7.16% | 0.81% | -6.83% |
| EBITDA | -2.50% | -1.62% | -7.14% | 1.03% | -6.59% |
| EPS Basic | 15.40% | 14.13% | 2.54% | 13.08% | 5.78% |
| Normalized Basic EPS | 14.06% | 12.21% | 2.68% | 11.30% | 5.86% |
| EPS Diluted | 15.40% | 14.13% | 2.54% | 13.08% | 5.78% |
| Normalized Diluted EPS | 14.06% | 12.21% | 2.68% | 11.30% | 5.86% |
| Average Basic Shares Outstanding | 22.04% | 16.58% | 8.73% | 7.53% | 8.16% |
| Average Diluted Shares Outstanding | 22.04% | 16.58% | 8.73% | 7.53% | 8.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |